About: Induction of protective immunity against severe acute respiratory syndrome coronavirus (SARS-CoV) infection using highly attenuated recombinant vaccinia virus DIs

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Induction of protective immunity against severe acute respiratory syndrome coronavirus (SARS-CoV) infection using highly attenuated recombinant vaccinia virus DIs Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Induction of protective immunity against severe acute respiratory syndrome coronavirus (SARS-CoV) infection using highly attenuated recombinant vaccinia virus DIs
Creator	Mizutani, Tetsuya Morikawa, Shigeru Nagata, Noriyo Tashiro, Masato Taguchi, Fumihiro Hasegawa, Hideki Miyamura, Tatsuo Ishii, Koji Suzuki, Tetsuro Takemori, Toshitada Tsunetsugu-Yokota, Yasuko
Source	Elsevier; Medline; PMC
abstract	Abstract SARS-coronavirus (SARS-CoV) has recently been identified as the causative agent of SARS. We constructed a series of recombinant DIs (rDIs), a highly attenuated vaccinia strain, expressing a gene encoding four structural proteins (E, M, N and S) of SARS-CoV individually or simultaneously. These rDIs elicited SARS-CoV-specific serum IgG antibody and T-cell responses in vaccinated mice following intranasal or subcutaneous administration. Mice that were subcutaneously vaccinated with rDIs expressing S protein with or without other structural proteins induced a high level of serum neutralizing IgG antibodies and demonstrated marked protective immunity against SARS-CoV challenge in the absence of a mucosal IgA response. These results indicate that the potent immune response elicited by subcutaneous injection of rDIs containing S is able to control mucosal infection by SARS-CoV. Thus, replication-deficient DIs constructs hold promise for the development of a safe and potent SARS vaccine.
has issue date	2006-08-01(xsd:dateTime)
bibo:doi	10.1016/j.virol.2006.03.020
bibo:pmid	16678878
has license	els-covid
sha1sum (hex)	0a65ff59f56fb97f85ede40797f7a06e17463ba0
schema:url	https://doi.org/10.1016/j.virol.2006.03.020
resource representing a document's title	Induction of protective immunity against severe acute respiratory syndrome coronavirus (SARS-CoV) infection using highly attenuated recombinant vaccinia virus DIs
has PubMed Central identifier	PMC7111839
has PubMed identifier	16678878
schema:publication	Virology
resource representing a document's body	covid:0a65ff59f56fb97f85ede40797f7a06e17463ba0#body_text
is schema:about of	named entity 'These' named entity 'SARS-CoV' named entity 'IgG' named entity 'ABLE TO' named entity 'FOLLOWING' named entity 'ELICITED' named entity 'RESULTS' named entity 'SARS-COV' named entity 'CAUSATIVE AGENT' named entity 'STRUCTURAL PROTEINS' named entity 'RDIS' named entity 'A GENE' named entity 'IDENTIFIED' named entity 'PROMISE' named entity 'IGA' named entity 'MICE' named entity 'REPLICATION' named entity 'SARS' named entity 'SUBCUTANEOUS ADMINISTRATION' named entity 'DIS' named entity 'TO CONTROL' named entity 'RECENTLY' named entity 'INDUCED' named entity 'SERIES' named entity 'VACCINATED' named entity 'RECOMBINANT' named entity 'ANTIBODIES' named entity 'SUBCUTANEOUS INJECTION' named entity 'SPECIFIC' named entity 'RESPONSE' named entity 'MUCOSAL' named entity 'T-CELL' named entity 'SAFE' named entity 'IGG' named entity 'PROTEIN ' named entity 'CHALLENGE' named entity 'ATTENUATED' named entity 'INFECTION' named entity 'DIS' named entity 'MUCOSAL INFECTION' named entity 'INDUCTION' named entity 'PROTECTIVE IMMUNITY' named entity 'HIGHLY' named entity 'USING' named entity 'CONTAINING' named entity 'ELICITED BY' named entity 'SIMULTANEOUSLY' named entity 'IGG ANTIBODY' named entity 'DEVELOPMENT' named entity 'ABSENCE OF' named entity 'ATTENUATED' named entity 'PROTECTIVE IMMUNITY' named entity 'IMMUNE RESPONSE' named entity 'S PROTEIN' named entity 'SERUM' named entity 'DEFICIENT' named entity 'VACCINIA' named entity 'RESPONSES' named entity 'SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS' named entity 'RECOMBINANT VACCINIA VIRUS' named entity 'STRAIN' named entity 'ENCODING' named entity 'THESE' named entity 'SARS VACCINE' named entity 'HOLD' named entity 'CORONAVIRUS' named entity 'HIGHLY' named entity 'INTRANASAL' named entity 'HIGH LEVEL' named entity 'MARKED' named entity 'CONSTRUCTED'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software